COVID -Recovery

ANZICS CTG Endorsed Study

COVID -Recovery

The COVID-Recovery Study

Study Description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus that emerged in 2019 and causes Coronavirus Disease 2019 (COVID-19). The rates of admission to an intensive care unit (ICU) are approximately 5% and the long-term outcomes of these patients are unknown. In order to improve quality of life of ICU survivors and ensure that physiotherapists apply appropriate treatment to reduce the cost of these surviving patients on the community, COVID-Recovery will conduct a longitudinal cohort study.

Active sub study – COVID-Recovery Persistent Critical Illness. A subset of adult patients with COVID-19 who were persistently critically ill, defined as a stay in ICU longer than 10 days, and enrolled in the COVID-Recovery study (the parent study) will be retrospectively enrolled in this nested cohort study. All patients eligible to participate in COVID Recovery Persistent Critical Illness will have hospital level data collected and those who agree to be contacted by phone will have a number of assessments to describe recovery, health-related quality of life, global, physical and cognitive function and anxiety and depression symptoms.

Management Committee

Carol Hodgson, Scott Bradley, Lisa Beach, Bernie Bissett, Ianthe Boden, Kimberley Haines, Lisa Higgins, Alice Jones, Lisa van der Lee, Marc Nickels, George Ntoumenopoulos, Thomas Rollinson, Shane Patman, Michelle Paton, Gemma Pound, Janani Sivasuthan, Peter Thomas, Claire Tipping, Heidi Buhr, Alison Bone

Administering Institution

Monash University – Australian and New Zealand Intensive Care Research Centre Department of Epidemiology and Preventive Medicine

Sample Size

284 patients


CTG2021-03, NCT04401254


Carol Hodgson email